Q4 Financial Results Overview: Comparing Lantheus (NASDAQ:LNTH) With Other Medical Devices & Supplies - Imaging and Diagnostics Companies

Analyzing Q4 Results: Lantheus and Its Industry Peers

Let’s take a closer look at how Lantheus (NASDAQ:LNTH) and other leading companies in the medical imaging and diagnostics sector performed during the recently concluded fourth-quarter earnings season.

Industry Overview

The medical devices and supplies sector, especially those focused on imaging and diagnostics, is known for its steady demand but also requires significant capital investment. These companies benefit from the ongoing need for diagnostic tools in healthcare, generating recurring income through consumables, service agreements, and equipment upkeep. However, they also face hurdles such as high initial development expenses, strict regulatory standards, and increasing pressure from healthcare providers to keep costs low. Looking forward, the industry is set to gain from technological innovations like artificial intelligence, which can improve diagnostic precision and streamline workflows, as well as from the growing need for imaging solutions due to an aging population. Nevertheless, potential reductions in healthcare spending, slower purchases of major equipment, and cybersecurity risks associated with connected devices could pose challenges for manufacturers.

Q4 Performance Snapshot

Among the four imaging and diagnostics companies tracked, the group delivered a modest fourth quarter, collectively surpassing revenue forecasts by 3.5%.

Despite these results, share prices have struggled, with the group’s average stock price dropping 8.2% since the latest earnings announcements.

Lantheus (NASDAQ:LNTH)

Lantheus Holdings is recognized for its innovative "Find, Fight and Follow" strategy in disease management. The company develops and markets radiopharmaceuticals and imaging agents that assist healthcare professionals in detecting, diagnosing, and treating various conditions.

For the quarter, Lantheus reported $406.8 million in revenue, marking a 4% increase from the previous year and exceeding analyst projections by 11%. However, despite this revenue beat, the company’s full-year outlook for both revenue and earnings per share fell well short of expectations, signaling a less robust quarter overall.

Mary Anne Heino, Lantheus’ CEO, commented, “In 2025, we achieved the critical objective of maintaining our leadership with PYLARIFY. We also broadened our commercial offerings with Neuraceq and expanded our pipeline through the acquisitions of Life Molecular Imaging and Evergreen Theragnostics.”

Lantheus Stock Performance

While Lantheus delivered the largest earnings beat among its peers, its full-year guidance was the weakest. The stock has risen 6.3% since the earnings release and is currently trading at $80.50.

Top Q4 Performer: GE HealthCare (NASDAQ:GEHC)

After separating from General Electric in 2023, GE HealthCare now delivers medical imaging systems, patient monitoring devices, diagnostic pharmaceuticals, and AI-powered healthcare solutions to medical facilities worldwide.

GE HealthCare posted $5.70 billion in revenue for the quarter, a 7.1% year-over-year increase and 1.7% above analyst estimates. The company not only exceeded expectations for full-year earnings per share but also delivered strong organic revenue growth.

GE HealthCare Stock Performance

GE HealthCare led its peers in revenue growth. Despite this strong performance, the market reacted negatively, with shares falling 7% since the earnings announcement. The stock is currently priced at $73.28.

Weakest Q4: Hologic (NASDAQ:HOLX)

Hologic, a leader in 3D mammography for breast cancer detection, specializes in diagnostic products, imaging systems, and surgical devices with a focus on women’s health.

For the quarter, Hologic reported $1.05 billion in revenue, up 2.5% from the previous year but missing analyst expectations by 2.1%. The company also fell short on earnings per share, making it the weakest performer in the group relative to analyst forecasts. The stock price has remained flat since the results and is currently at $75.58.

QuidelOrtho (NASDAQ:QDEL)

Formed by the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho offers a range of diagnostic testing solutions, from rapid point-of-care tests to advanced laboratory systems.

QuidelOrtho’s quarterly revenue reached $723.6 million, a 2.2% year-over-year increase and 3.2% above analyst projections. While the company raised its full-year guidance more than any of its peers, it also posted the slowest revenue growth and missed full-year earnings per share targets. The stock has declined 32.9% since the earnings report and is now trading at $19.33.

Looking for Strong Investment Opportunities?

If you’re interested in companies with solid fundamentals, explore our Top 6 Stocks to add to your watchlist. These businesses are well-positioned for growth, regardless of broader economic or political shifts.

The StockStory analyst team, comprised of experienced investment professionals, leverages data-driven analysis and automation to deliver timely, high-quality market insights.